And another set of guesses on which drugs will be next up for price controls
And Michigan is set to be the next 340B battleground. Could the Wolverine State learn from the experience of the Gopher State?
And a breathless Reuters story suggests that industry thinks IRA fixes are in play during Trump 2.0
Plus links on gene therapy financing, BMS' 340B statement, and more importation skepticism
Otherwise: 🦃🦃🦃
Plus the Biden administration makes a move to cover obesity meds in Medicare and Medicaid ... but will it matter?
The data has some gaps -- as the state recognizes -- but it's still a fantastic resource for seeing how the program operates at a more granular level
And trying to catch up on everything from IP reform to 340B messaging
And the Oregon PDAB continues its shenanigans
And PBM news is back with a vengeance
Plus some math from the former head of the CBO helps estimate how much tax revenue is being lost because of out-of-control 340B growth
And Lilly joins J&J in taking legal actions to move to a more accountable 340B system